News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stressgen Biotechnologies Corporation (SSB.TO) Release: TSX Issues Bulletin Confirming Substitutional Listing


3/30/2006 11:24:46 AM

VICTORIA, BC and SAN DIEGO, CA, March 29 /PRNewswire-FirstCall/ - Stressgen Biotechnologies Corporation ("Stressgen" or the "Corporation") announced today that the TSX has issued a bulletin confirming the listing on the TSX of Stressgen's common shares and warrants in substitution for the presently listed common shares and warrants of GVIC Publications Ltd. (formerly "Stressgen Biotechnologies Corporation") ("GVIC Publications").

The Corporation's common shares and warrants will commence trading on the TSX at the opening on Thursday, March 30, 2006 under the symbol "SSB", and the presently listed common shares and warrants of GVIC Publications will be delisted at that time. A copy of the TSX bulletin may be found on the TSX website at www.tsx.com.

The substitutional listing follows the March 23, 2006 completion of the Corporation's previously announced corporate reorganization involving Stressgen, GVIC Publications and 0747036 B.C. Ltd. ("Investor"), an affiliate of Glacier Ventures International Corp., an information communications company listed on the TSX.

Following completion of the reorganization, Stressgen has established a new SEDAR profile. Historical information concerning the Corporation's management, business and operations can be found on the SEDAR website at www.sedar.com under GVIC Publications' SEDAR profile.

About Stressgen Biotechnologies Corporation

Stressgen is developing innovative therapeutics for the treatment of viral infections, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol SSB. For more information about Stressgen, please visit the Company's website at www.stressgen.com.

Stressgen Contact: Donna Slade Director, Investor Relations 6055 Lusk Boulevard San Diego, CA USA 92121 Tel: 858/202-4900 Dir: 858/202-4945 Fax: 858/450-6849 dslade@stressgen.com

Stressgen Biotechnologies Corp.

CONTACT: Donna Slade, Director, Investor Relations, 6055 Lusk Boulevard,San Diego, CA, USA 92121, Tel: (858) 202-4900, Dir: (858) 202-4945, Fax:(858) 450-6849, dslade@stressgen.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES